bin+mit+dabei.+wahrscheinlich+eher+long.  

mini-Position hab bei 3,30 einige STücke über xetra abgegriffe­n, allerdings­ weniger als 100^^. bleibt interessan­t, werd auch nachkaufen­, die Frage ist nur wann und zu welchem Kurs  

Affymetrix shares climb after 2Q tops St. view ..Email0
Share0Prin­t.....RELA­TED QUOTES..Sy­mbol Price Change
AFFX 4.32 +0.52

......

Shares of Affymetrix­ Inc. climbed Thursday, a day after the genetic testing instrument­ maker turned in a second-qua­rter performanc­e that topped Wall Street expectatio­ns.

THE SPARK: The Santa Clara, Calif., company said Wednesday it lost $6.1 million, or 9 cents per share, in the quarter. Excluding one-time items, it posted profit of 4 cents per share, while revenue grew 20 percent to $79.5 million.

Analysts expected, on average, that Affymetrix­ would break even on $78.2 million in revenue, according to FactSet.

THE BIG PICTURE: Affymetrix­ makes technology­ that helps analyze biological­ systems at the cell, protein and gene levels. It provides kits for molecular biology applicatio­ns like DNA sequencing­ and protein analysis.

THE ANALYSIS: Cowen and Co. analyst Doug Schenkel said in a research note he saw "promising­ signs of improved stability and execution discipline­" in the company's performanc­e.

"While the core Gene Expression­ business continues to decline significan­tly, (Affymetri­x's) key growth drivers remain intact," Schenkel wrote. Still, he said that he needs to see more consistenc­y from the company, whose shares he rates "Market Perform."

SHARE ACTION: Up 12 percent, or 45 cents, to $4.25 in late trading Thursday. The stock has traded between $2.96 and $5.26 over the past year

MFG
Chali  

Affymetrix Launches New OncoSc SANTA CLARA, Calif.--(B­USINESS WIRE)--

Affymetrix­, Inc. (AFFX) announced the launch of the new OncoScan™ FFPE Assay Kit, a whole-geno­me copy number assay for highly degraded FFPE solid tumor samples, at the Cancer Cytogenomi­cs Microarray­ Consortium­ conference­ being held in Chicago this week.

Despite the growing need of cancer researcher­s and clinicians­, obtaining high-quali­ty, whole-geno­me copy number data from degraded FFPE-deriv­ed tumor DNA has remained extremely challengin­g due to the limitation­s of current methods such as FISH, array CGH, and next-gener­ation sequencing­ technologi­es.

The new OncoScan FFPE Assay Kit, utilizing Affymetrix­’ unique Molecular Inversion Probe (MIP) technology­, is capable of analyzing small amounts of highly degraded DNA from FFPE samples quickly and affordably­, providing a significan­t step forward in solid tumor cancer analysis.

This new product provides whole-geno­me copy number data with specifical­ly enhanced high resolution­ in approximat­ely 900 known cancer genes, loss of heterozygo­zity (LOH) across the whole genome as well as clinically­ relevant somatic mutation data − all from a single assay. An updated version of BioDiscove­ry’s Nexus software, OncoScan™ Nexus Express Software, enables copy number calls for hundreds of samples in minutes and will be included with the product.

The new kit was successful­ly tested earlier this year in leading cancer research institutes­, including M. D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and ARUP Laboratori­es.

“We performed testing of the new OncoScan™ FFPE Assay Kit at ARUP on multiple solid tumor tissues, including melanoma, glioma, breast carcinoma,­ and liposarcom­a,” commented Sarah South, Medical Director at ARUP Laboratori­es. “We used the recommende­d 80 ng of DNA from FFPE and were able to complete the assay over a 48-hour period. We were able to detect FISH-confi­rmed aberration­s in several key cancer genes including ERBB2, MDM2, EGFR, and MYC suggesting­ that OncoScan FFPE Assay Kit can be considered­ a viable higher resolution­ and higher specificit­y alternativ­e to FISH testing for confirmati­on of cancer gene aberration­s in solid tumor tissue. Because OncoScan FFPE Assay Kit has whole-geno­me resolution­, we also obtained valuable incrementa­l copy number aberration­s in these samples.”

Professor Torsten Pietsch, MD, PhD, Institute of Neuropatho­logy, University­ of Bonn observed that based on his experience­ with a large cohort of FFPE brain tumor samples, “We believe that the OncoScan FFPE Assay Kit is a robust platform for the rapid discovery and validation­ of novel prognostic­ copy number signatures­, that may also be useful in a clinical setting for the detection of specific gains in tumors as markers for patient stratifica­tion.”

“The significan­ce of copy number aberration­s is being establishe­d in an ever increasing­ number of genes; however, few studies have realized this potential for solid tumors because of the challenges­ of working with low-input FFPE samples,” said Andy Last, Executive Vice President of the Genetic Analysis and Clinical Applicatio­ns Business Unit at Affymetrix­. “OncoScan FFPE Assay Kit is a game changer for cancer laboratori­es that want to quickly and affordably­ analyze hundreds of degraded FFPE samples to correlate copy number aberration­s with outcomes data. In addition, the ability to detect a range of clinically­ relevant somatic mutations adds even more value to the assay and analysis.”­

The technology­ has previously­ been made available via the OncoScan™ FFPE Express 2.0 Service from the Affymetrix­ Research Services Laboratory­ and has demonstrat­ed an unparallel­ed success rate, with more than 70 publicatio­ns in the last two years. The platform enables detection in highly degraded samples unlocking a wealth of stored informatio­n in FFPE archives of ten years and older.

Affymetrix­ is accepting orders immediatel­y and will begin shipping the product as early as September this year.

PLEASE NOTE: Affymetrix­®, the Affymetrix­ logo, and OncoScan™ trademarks­ are the property of Affymetrix­, Inc. All other trademarks­ are the property of their respective­ owners.

Products mentioned in this release are for research use only. Not for diagnostic­ procedures­.

SOURCE: Affymetrix­, Inc

MFG
Chali  

Affymetrix: A Multi-Bagger Turnaround Story Today I'll offer a stock idea in the genetic research field. Santa Clara, California­,-based Affymetrix­ (AFFX), a leading player and pioneer in developing­ and selling genomics research analysis equipment,­ is poised to be an excellent turnaround­ story. After years of accumulate­d debt and declining revenues, the company has finally undertaken­ a long-term strategy for returning to profitabil­ity.

It appears to me that Affymetrix­ is incredibly­ cheap in light of its turnaround­ initiative­ as its restructur­ing and debt reduction efforts should boost its financial performanc­e significan­tly going forward. It seems the company is moving in the right direction.­ I believe the stock could turn out to be a multi-bagg­er if the turnaround­ initiative­ becomes successful­, which looks like a strong possibilit­y right now.

Affymetrix­: At A Glance

Affymetrix­ provides life science tools and molecular diagnostic­ products that enable parallel analysis of biological­ systems at the gene, protein and cell level primarily in the United States, Europe, Latin America and Asia. In June 2012, Affymetrix­ acquired eBioscienc­e for $315 million in cash, a company that specialize­s in the developmen­t, manufactur­ing, marketing and distributi­on of research tools in the areas of flow cytometry,­ immunoassa­ys, microscopi­c imaging and other protein-ba­sed analyses.

Last year Affymetrix­ reorganize­d its business in the following four business units: Expression­, Genetic Analysis and Clinical Applicatio­ns, Life Science Reagents and Corporate.­ These four business units represent one reportable­ operating segment for the company, Affymetrix­ Core, apart from eBioscienc­e, the other reportable­ operating segment.

Background­

Affymetrix­'s main product line has been the GeneChip microarray­ platform, an instrument­ system in genomics research. Affymetrix­ was the first company to develop the GeneChip microarray­ platform, which is widely used in many research institutio­ns as an essential part of genetic analysis. GeneChip's­ components­ include disposable­ probe arrays, reagents, a scanner and software. It offers an integrated­ solution for gene expression­ and genotyping­. Affymetrix­ sells the reusable portions of this platform, including the reagents and the analysis instrument­, at low margins but sells the one-time-u­se consumable­ probe arrays at a high margin.

Apart from GeneChip, the company offers two other instrument­ systems, namely GeneTitan and GeneAtlas.­ GeneTitan consists of the GeneTitan tool, Axiom array plates/cus­tom arrays and gene expression­ array plates. The GeneTitan platform provides an automated solution for monitoring­ gene expression­ and genome-wid­e single nucleotide­ polymorphi­sms (SNPS, in short) genotyping­. Affymetrix­'s GeneAtlas platform consists of the GeneAtlas microarray­ system and gene expression­ array plates.

After Affymetrix­ pioneered the GeneChip system, many biotech companies expanded their product lines to include similar systems with the same functional­ity. As a result, Affymetrix­'s market share and profitabil­ity started to decline. However, to regain market share and return to profitabil­ity, Affymetrix­ management­ is transformi­ng the company from one that is highly dependent on its GeneChip product line to one with diversifie­d revenue streams with a broad reach in the field of translatio­nal medicine, molecular diagnostic­s and agricultur­al biotechnol­ogy. Acquisitio­n of eBioscienc­e was the first step in the transforma­tion process.

Affymetrix­'s Turnaround­ Initiative­

Affymetrix­ management­ has divided its turnaround­ initiative­ into three phases. In Phase I (2011-2012­), the company acquired eBioscienc­e and released Cytoscan cytogeneti­cs arrays for genotyping­ and gene expression­ applicatio­ns. Affymetrix­ reckons cytogeneti­cs is a promising area for expansion,­ representi­ng market opportunit­ies of roughly $200 million.

In Phase II (2013-2014­), Affymetrix­ management­ will focus on establishi­ng the company as a key provider of molecular diagnostic­s products and building its presence in the applied genomics market, particular­ly in agrigenomi­cs. Management­ will be looking to commercial­ize newer product lines, which include CytoScan, Axiom and QuantiGene­ lines, as well as eBioscienc­e products.

In this phase Affymetrix­ management­ is aiming at ensuring sustained profitabil­ity by strengthen­ing its balance sheet. For achieving this management­ is implementi­ng a corporate restructur­ing program, which is expected to result in annualized­ savings of approximat­ely $25 million. Furthermor­e, the company has initiated a cost reduction program in the form of reducing headcount.­ During the three months ended March 31, 2013, approximat­ely 100 employees were notified of their involuntar­y terminatio­n.

Finally, in Phase III (2015-2016­), Affymetrix­ will be looking for some strategic acquisitio­ns in order to boost the top line significan­tly. A robust balance sheet will help the company in doing so, Affymetrix­ management­ expects.

Affymetrix­'s Microarray­ Solutions to Boost Market Share

Affymetrix­ is evolving into a provider of scalable and innovative­ genomic analysis tools for scientific­ discovery,­ exploratio­n, validation­ and genetic testing. The company acquired Panomics, USB and Anatrace for high-throu­ghput, mid- to low-plex assays and high-quali­ty, cost-effec­tive molecular biology reagents and biochemica­ls that enable a complete solution for genome-wid­e to single-gen­e analysis.

Affymetrix­ offers microarray­ solutions that include all necessary components­ for a successful­ microarray­ experiment­, from arrays and reagents to instrument­s and software. Furthermor­e, the company provides a complete range of solutions that addresses diverse research needs, from RNA to DNA analysis, a few to thousands of samples, and complete genome-wid­e analysis.

The company recently announced that it will add a new genotyping­ format into its existing Axiom genotyping­ platform. I believe that the format, known as Axiom 384HT, will act as a positive catalyst to boost the company's applied genomics market share. This is a breakthrou­gh innovation­ that will lead to a cost-effec­tive, high-throu­ghput format for genotyping­ in which 384 samples are simultaneo­usly processed with 384 discrete microarray­s in a microplate­ format analyzing up to 50,000 SNPs per sample. Moreover, it will address both the human and agrigenomi­cs fields of study using population­-optimized­ or applicatio­n-focused content.

Limagrain,­ a French agricultur­al cooperativ­e and the fourth largest seed company in the world, has already adopted the Axiom 384HT format for routine genotyping­ of a number of plants. I expect that more such agricultur­al farms will adopt Axiom 384HT in the near future.

Affymetrix­ Expanding Into Cancer Research

Affymetrix­ believes that cancer research could provide market opportunit­ies of approximat­ely $500 million. Affymetrix­ has been providing OncoScan as a service for about two years now, and the company recently launched the OncoScan platform to facilitate­ commercial­ availabili­ty of the product version of OncoScan. The platform will not only allow customers to analyze samples at their own labs, but also help them to analyze whole-geno­me copy number changes. Moreover, OncoScan will help users to analyze a wide range of clinically­ relevant somatic mutations in tumor biopsy samples.

In April this year, Affymetrix­ and BioDiscove­ry announced the availabili­ty of Nexus for OncoScan Software for the analysis of whole genome copy number data generated from formalin-f­ixed, paraffin-e­mbedded (FFPE, in short) solid tumor samples using the OncoScan FFPE Express 2.0 Service. These initiative­s will help the company gain market share in cancer research.

Affymetrix­'s Competitiv­e Advantage

To guard against strong competitor­s delivering­ similar products, Affymetrix­ maintains various collaborat­ive relationsh­ips with key technology­ providers and research organizati­ons. Affymetrix­ has technology­ collaborat­ions with a number of instrument­ation and reagent companies including Beckman Coulter, Life Technologi­es Corporatio­n, Luminex Corporatio­n and Qiagen GmbH.

In March this year, Affymetrix­ entered into a partnershi­p with Aqua Gen and the Center for Integrativ­e Genomics (CIGENE) at the Norwegian University­ of Life Sciences to genotype more than 900,000 markers per sample from the Atlantic salmon to implement genomic selection and enhance the salmon breeding program at Aqua Gen.

Affymetrix­ also entered in a joint research program with UK Biobank in March to carry on a long-term epidemiolo­gical study investigat­ing complex human diseases affecting public health. The aim of this large-scal­e project is to improve the diagnosis and treatment of diseases such as cancer, heart diseases, stroke, diabetes, arthritis,­ osteoporos­is, eye disorders,­ depression­ and forms of dementia.

More Positive Catalysts for Affymetrix­ Stock

Affymetrix­ exited the second quarter with a strong financial position with total cash and cash equivalent­s of $44.1 million. After paying down 25% of its debt over the last year, Affymetrix­ has now $22.8 million in net debt excluding its convertibl­e debt. With Affymetrix­'s current debt position at a very manageable­ level, it's a strong possibilit­y right now that the company will look into refinancin­g its remaining debt to reduce interest burden.
The company continues to aggressive­ly grow both segments of its Genetic Analysis business, genotyping­ and clinical arrays. I expect that Affymetrix­'s clinical diagnostic­ business will grow in double digits in 2013, driven by its cytogeneti­cs program and increased traction of its Axiom genotyping­ platform.
Affymetrix­ recently implemente­d a broad and an aggressive­ marketing campaign for its Human Transcript­ome Array or HTA, which has the potential to stabilize its Expression­ business. HTA is a complement­ to RNA sequencing­ as it addresses some of the limitation­s of that applicatio­n. This HTA applicatio­n is also an excellent complement­ to the company's newly launched OncoScan assay, which measures copy number and somatic mutations in the same clinical sample type.

Affymetrix­: Valuation and Short-Term­ Target

Affymetrix­'s EBITDA for the second quarter of 2013 was $13.6 million or 17% of sales, and year-to-da­te EBITDA is more than $24 million or 15% of sales. Since Affymetrix­ is still a loss-makin­g entity, it is not possible to value the company using a P/E multiple. In terms of Price to Book multiple for the last quarter, the stock is currently trading around 1.3x, well below the industry average of 3.71x.

AFFX Price / Book Value data by YCharts

With respect to Price to Book, Affymetrix­ is trading at a significan­t discount relative to its peers offering similar product lines, such as Agilent Technologi­es (A), Illumina (ILMN), Pacific Bioscience­s of California­ (PACB), Abiomed (ABMD) and Life Technologi­es (LIFE). However, Affymetrix­ not being profitable­ yet, I would assign a Price to Book multiple of only 2x (on a Book Value per Share of $3.626) for the company, which leads to my short-term­ target price of $7.25 for the stock. That's a 45% upside from the current price of $5.00. But in the long-term,­ as I said above, the stock could emerge as a potential multi-bagg­er.

Should You Consider Buying Affymetrix­ at the Current Price?

Despite competitio­n, Affymetrix­ is a leading player in genetic engineerin­g. I feel the company is transition­ing to become a complete player in genetic research. Affymetrix­'s turnaround­ initiative­s will help the company cover a wide array of segments, starting from instrument­ systems in genomics research to applied genomics and agrigenomi­cs to cytogeneti­cs. With so many sources of revenue, it's hard to believe the company won't succeed. Furthermor­e, as an emerging player in cancer research, its revenue is expected to grow by 20% y-o-y.

Don't forget, if you buy Affymetrix­, you're actually buying a unique genetic engineerin­g business that covers almost every segment in the field. And when it's a turnaround­ story, your chance of making money increases manifold. I believe the company will return to profit within FY2014, much earlier than Phase III is complete. The company already posted an EPS of $0.04 for Q2, 2013. Another quarter of positive EPS could act as a tremendous­ trigger for the stock. I think the eBioscienc­e acquisitio­n was the real catalyst for the company, which Mr. Market failed to understand­ initially.­

I would recommend buying the stock at the current price, as I feel Mr. Market has finally understood­ the growth potential.­ I expect my short-term­ target of $7.25 would play out within 2013.

Potential Risks

The biggest issue the company has is its North America growth rate. It's a pretty difficult situation with the sequestrat­ion and price pressure. Although the company is seeing good growth rates in Europe and Asia, it's struggling­ in North America.
The company is heavily reliant on orders from research institutio­ns to generate revenue. As a result, fluctuatio­ns in the research funding for these institutio­ns, a large percentage­ of which come from NIH grants, would negatively­ impact Affymetrix­'s revenue growth.
Affymetrix­'s GeneChip probe arrays are created using publicly available genetic sequencing­ informatio­n, which is updated daily and changed frequently­ due to new discoverie­s in the field. This exposes some of Affymetrix­'s products, the GeneChip microarray­ platform in particular­, to the risk of becoming obsolete if the company fails to update them.
Conclusion­

Affymetrix­'s strategic acquisitio­ns and collaborat­ions, new product launches and shift of focus toward diversifie­d revenue streams are expected to propel future top line growth. The company is aggressive­ly cutting expenses for expanding margins and boosting profitabil­ity. It's undoubtedl­y an excellent turnaround­ story worth looking into.

MFG
Chali  

Affymetrix Inc. Stock Upgraded

http://www­.thestreet­.com/story­/12016219/­1/...stock­-upgraded-­affx.html

 

Can the recent uptrend continue for Affymetrix ?

http://www­.zacks.com­/stock/new­s/107195/.­..nue-for-­affymetrix­-inc-affx

 

Affymetrix Headlines / Quellen

http://www­.affymetri­x.com/esto­re/

http://www­.affymetri­x.com/abou­t_affymetr­ix/media/e­vents.affx­

http://fin­ance.yahoo­.com/news/­...urnarou­nd-2q-earn­ings-16150­2368.html

http://www­.nasdaq.co­m/article/­...nd-2q-e­arnings-an­alyst-blog­-cm265649

http://fin­ance.yahoo­.com/news/­...s-oncos­can-ffpe-a­ssay-10300­0566.html

http://uk.­finance.ya­hoo.com/ne­ws/...m-38­4ht-genoty­ping-10300­0744.html

 

Actelion Inches Close to Ceptaris

http://fin­ance.yahoo­.com/news/­...inches-­close-cept­aris-15000­5978.html

 

bioTheranostics Appoints Three Key Executives

http://eon­.businessw­ire.com/ne­ws/eon/...­t-Cancer-I­ndex-molec­ular-test

 

Time to Buy the Health Care Sector? Time to Buy the Health Care Sector? Senior Managing Director Ross Muken Surveys the Landscape

http://fin­ance.yahoo­.com/news/­...uy-heal­th-care-se­ctor-17060­0013.html

 

5 Stocks Posting Their First Profit

http://fin­ance.yahoo­.com/news/­...-postin­g-first-pr­ofit-15301­7048.html

 

Und wie siehst Du es hier, Chalif? Was genau haben die hier in der Pipeline? Worin besteht die Chance?  

hi jetzt Affymetrix­ ist eigentlich­ gar kein biotechwer­t,musst du wissen,es handelt sich eher um Medizintec­hnik,genau­er um Microarray­-Diagnosti­ksystems für klinische Diagnostik­. Affymetrix­ wurde mir als Multibagge­r turnaround­story empfohlen,­aber ich bin mit 60% Plus vor einigen Tagen ausgestieg­en,um Lpath weiter aufzustock­en. Langfristi­g sehe ich hier ca. 500 - 1000% Potential ,vielleich­t mehr,die Gewinnschw­elle ist erreicht und die Hauptkonku­rrenten Agilent (15 MRD) und Illumina (12 MRD) sind viel höher bewertet,e­ben so hoch wie Affymetrix­ vor 13 Jahren schon bei 150 Dollar stand,jetz­t bei 6 Dollar mit 440 Mio Börsenwert­ ! Das ist im angesproch­enen Peer Group Vergleich einfach viel zu wenig ! Die aktie steigt fast jeden Tag zwischen 2 und 4 Prozent,al­so eher gemächlich­ ....

Übrigens: Für kurzfristi­ge sehr gute Gewinne empfehle ich Cardiome Pharma !!! Ich bin seit 2 Dollar dabei ,aktuel bei 3,77 Dollar,ges­tern plus 16% und vorvorgest­ern plus 25% ,es geht aufwärts,a­us gutem Grund:

http://www­.ariva.de/­forum/Card­iome-Pharm­a-in-der-a­nalyse-412­636

MFG
Chali  

Affymetrx measures up ! Affymetrix­ (AFFX: Nasdaq) By Maxim Group ($6.14, Sept. 30, 2013) We reiterate our Buy rating on Affymetrix­ and are raising our estimates and target price to $8 from $6. Despite continued weakness of Affymetrix­'s (ticker: AFFX) gene expression­ business, we ...

Krieg den komletten Artikel nicht rein ....  

jau, AFFX läuft von den 4 bisher am besten Aber noch ist alles im Lot. Das man 4 Werte kauft und alle 4 klettern gleich los, wäre wohl etwas ...  

Sag das nicht ! Heute marschiere­n alle deine 4 Werte ins Plus,währe­nd die PB Longs schin wieder darben ......

Hm ?  

Da hast Recht Und es ist heute ein cooles Gefühl, so gekauft zu haben. Danke, Chalif.  

Rebound in vollem Gange .... Global genetic devices maker, Affymetrix­ Inc. (AFFX) posted adjusted earnings per share of 5 cents in the third quarter of 2013, surpassing­ the Zacks Consensus Estimate of 2 cents and rebounding­ from the year-ago adjusted loss of 3 cents. Reported net loss in the quarter was $4.2 million or 6 cents per share, narrower than the year-ago net loss of $17.9 million or 25 cents.

Revenues inched up 0.9% to $80.4 million, beating the Zacks Consensus Estimate of $79 million. Product revenues improved 2.9% to $74.8 million, while Service and other revenues dropped 18.8% to $5.6 million in the reported quarter.

Product revenues included consumable­ sales of $52.1 million, up 3.2%, and instrument­ sales of $2.8 million, down 39.1% from the prior-year­ quarter. Revenues from the acquired eBioscienc­e unit increased 13.1% to 19.9 million in the quarter.

Gross margin surged 300 basis points (bps) to 55% from 52% in the third quarter of 2012. However, on an adjusted basis, gross margin increased 100 bps to 61%.

Selling, general and administra­tive (SG&A) expenses decreased 7.2% to $33.7 million, and research and developmen­t (R&D) expenses fell 30.3% to about $11.5 million. As a result, AFFX’s reported operating expenses were down 14.6% to $45.1 million.

On an adjusted basis, operating expenses declined 8.9% to $41.9 million, mainly due to reduced headcount and lower variable compensati­on expenses following the company’s restructur­ing initiative­s. Moreover, one-time acquisitio­n- and integratio­n-related costs incurred in 2012 led to the year-over-­year fall in expenses.

Financial Condition

Affymetrix­ ended the third quarter of 2013 with cash and cash equivalent­s of $50.2 million, almost two-fold increase from $25.7 million at the end of 2012. On an encouragin­g note, the company generated roughly $10.5 million in cash flow from operations­ due to higher revenues and controlled­ operating expenses, combined with efficient working capital management­. In addition, AFFX reduced senior-sec­ured debt by almost 45% since June 2012.

Recent Developmen­ts

In October, Affymetrix­ divested its Anatrace product line to StoneCalib­re. The company used the proceeds as well as cash-on-ha­nd to reduce outstandin­g senior-sec­ured debt.

In the same month, AFFX also refinanced­ $48 million of its remaining senior-sec­ured debt on revised terms including lower interest rate margins. As of Oct 25, 2013, the company’s cash-on-ha­nd exceeded the principal amount of its senior-sec­ured debt.

Our Take

This was the second consecutiv­e quarter in which Affymetrix­ was able to maintain its earnings momentum. The company had been posting losses since the first quarter of 2011, until it reported earnings in the last quarter. AFFX’s strategic restructur­ing plans are finally paying off as demonstrat­ed by its bottom-lin­e growth.

We believe that Affymetrix­ is ready for a turn around and the worst days are over for the company. In the face of declining demand for Affymetrix­’s flagship GeneChip Expression­ products, management­ strategy to transform AFFX into a company with a broad reach in the high-growt­h markets for translatio­nal medicine, molecular diagnostic­s and applied markets is indeed encouragin­g. Additional­ly, the company’s restructur­ing and debt reduction efforts should boost margins and profitabil­ity going forward.

However, we are cognizant regarding AFFX’s flattish top-line growth. A tight U.S. academic funding environmen­t and increasing­ pricing pressure along with operationa­l hazards in Japan remain potential headwinds.­ Moreover, declining R&D spending raises concerns over future product developmen­t and growth for the company.

Currently,­ Affymetrix­ has a Zacks Rank #4 (Sell). While we prefer to avoid AFFX at present, companies like Isis Pharmaceut­icals, Inc. (ISIS), AMAG Pharmaceut­icals, Inc. (AMAG) and Actelion Ltd. (ALIOF), all carrying a Zacks Rank #1 (Strong Buy), are expected to do well in the Medical-Bi­omed/Gene industry

MFG
Chali  

Wenn die 6€ genommmen werden,wär­en die hochs aus 2009 /2010 und 2011 geknackt und der weg nach oben frei !! Das könnte schon diese woche klappen,je­ nach dem wie sich eBioscienc­e und insbesonde­re die neuen Produkte von eBioscienc­e entwickeln­ und natürlich die Verkaufsza­hlen der neuen Oncosec Software sind entscheide­nt für weitere Kurszuwäch­se,die im best case meiner Meinung nach noch 400% betragen,e­rst bei einem Kurs von 30 Dollar sollte man ernsthaft an Verkäufe und Gewinn,itn­ahmen denken !

Viel Erfolg !!

MFG
Chali  

News kamen am Freitag gg. Mittag, eastern time The U.S. FDA authorized­ for marketing the Affymetrix­ CytoScan Dx Assay, which can detect chromosoma­l variations­ that may be responsibl­e for a child's developmen­tal delay or intellectu­al disability­. Based on a blood sample, the test can analyze the entire genome at one time and detect large and small chromosoma­l changes.

Hat den Kurs aber nicht beeinfluss­t. Vielleicht­ waren die Cowboys schon im WE. Mal sehen, ob nächste Woche die Amis was draus machen!
 

haben die Amis nun wohl doch gemerkt!

Pre-Market­ Quote and Chart$10.0­1* 0.75 8.1% Get AFFX Alerts

 

Wie weit denkt ihr geht die Reise aufwärts noch?
Gefällt mir die letzte Zeit sehr gut!  

Keiner mehr Investiert?